Treatment of episodes of hereditary angioedema with C1 inhibitor: Serial assessment of observed abnormalities of the plasma bradykinin-forming pathway and fibrinolysis

Annals of Allergy, Asthma and Immunology

Volumn 104, Issue 1, 2010, Pages 50-54

  Joseph, Kusumam ^a   Tholanikunnel, Tracy E ^a   Kaplan, Allen P ^a  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA 2 ANTIPLASMIN; BLOOD CLOTTING FACTOR 12; BLOOD CLOTTING FACTOR 12A; BRADYKININ; COMPLEMENT COMPONENT C1S INHIBITOR; COMPLEMENT COMPONENT C4A; KALLIKREIN; PLASMIN;

ANGIONEUROTIC EDEMA; ARTICLE; BLOOD LEVEL; BLOOD SAMPLING; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG INFUSION; FIBRINOLYSIS; HUMAN; IN VITRO STUDY; PRIORITY JOURNAL; SWELLING; TREATMENT OUTCOME;

EID: 76749120402     PISSN: 10811206     EISSN: 15344436     Source Type: Journal    
DOI: 10.1016/j.anai.2009.11.014     Document Type: Article

References (37)

1. Kaplan AP, Joseph K, Silverberg M. Pathways for bradykinin formation and inflammatory disease. J Allergy Clin Immunol. 2002;109:195-209.
2. Fields T, Ghebrehiwet B, Kaplan AP. Kinin formation in hereditary angioedema plasma: evidence against kinin derivation from C2 and in support of "spontaneous" formation of bradykinin. J Allergy Clin Immunol. 1983;72:54-60.
3. Shoemaker LR, Schurman SJ, Donaldson VH, Davis AE 3rd. Hereditary angioneurotic oedema: characterization of plasma kinin and vascular permeability-enhancing activities. Clin Exp Immunol. 1994;95:22-28.
4. Nussberger J, Cugno M, Cicardi M, Agostoni A. Local bradykinin generation in hereditary angioedema. J Allergy Clin Immunol. 1999;104: 1321-1322.
5. Gadek JE, Hosea SW, Gelfand JA, et al. Replacement therapy in hereditary angioedema: a successful treatment of acute episodes of angioedema with partly purified C1 inhibitor. N Engl J Med. 1980;302:542-546.
6. Bowen T, Cicardi M, Farkas H, et al. Canadian 2003 international consensus algorithm for the diagnosis, therapy, and management of hereditary angioedema. J Allergy Clin Immunol. 2004;114:629-637.
7. Joseph K, Tuscano TB, Kaplan AP. Studies of the mechanism of bradykinin generation in hereditary angioedema plasma. Ann Allergy Asthma Immunol. 2008;101:279 -286.
8. Ghebrehiwet B, Silverberg M, Kaplan AP. Activation of the classical pathway of complement by Hageman factor fragment. J Exp Med. 1981;153:665- 676.
9. Ghebrehiwet B, Randazzo BP, Dunn JT, Silverberg M, Kaplan AP. Mechanism of activation of the classical pathway of complement by Hageman factor fragment. J Clin Invest. 1983;71:1450 -1456.
10. Zuraw B. Clinical practice: hereditary angioedema. N Engl J Med. 2008;359:1027-1036.
11. Frank MM. Hereditary angioedema: the clinical syndrome and its management in the United States. Immunol Allergy Clin North Am. 2006; 26:653- 668.
12. Joseph K, Tholanikunnel BG, Kaplan AP. Factor XII-independent cleavage of high-molecular weight kininogen by prekallikrein and inhibition by C1 inhibitor. J Allergy Clin Immunol. 2009;124:143-149.
13. Cugno M, Hack CE, deBoer JP, et al. Generation of plasmin during attacks of hereditary angioedema. J Lab Clin Med. 1993;121:38-43.
14. Agostoni A, Aygoren-Pursun E, Berkley KE, et al. Hereditary and acquired angioedema: problems and progress: proceedings of the third C1 esterase inhibitor deficiency workshop and beyond. J Allergy Clin Immunol. 2004;114:S51-S131.
15. Mandle RJ Jr, Kaplan AP. Hageman factor substrates: human plasma prekallikrein: mechanism of activation by Hageman factor and participation in Hageman factor-dependent fibrinolysis. J Biol Chem. 1997; 252:6097- 6104.
16. Ichinose A, Fujikawa K, Suyama T. The activation of pro-urokinase by plasma kallikrein and its inactivation by thrombin. J Biol Chem. 1986; 261:3486 -3489.
17. Smith D, Gilbert M, Owen WG. Tissue plasminogen activator release in vivo in response to vasoactive agents. Blood. 1985;66:835- 839.
18. Kaplan AP, Austen KF. A prealbumin activator of prekallikrein, II: derivation of activators of prekallikrein from active Hageman factor by digestion with plasmin. J Exp Med. 1971;133:696 -712.
19. Kleniewski J, Donaldson VH. Comparison of human high molecular weight kininogen digestion by plasma kallikrein and by plasmin: a revised method of purification of high molecular weight kininogen. J Lab Clin Med. 1987;109:469-479.
20. Wallace EM, Perkins SJ, Sim RB, Willis AC, Feighery C, Jackson J. Degradation of C1-inhibitor by plasmin: implications for the control of inflammatory processes. Mol Med. 1997;3:385-396.
21. Gelfand JA, Sherins RJ, Alling DW, Frank MM. Treatment of hereditary angioedema with danazol: reversal of clinical and biochemical abnormalities. N Engl J Med. 1976;295:1444 -1448.
22. Sheffer AL, Fearon DT, Austen KF. Clinical and biochemical effects of stanozolol therapy for hereditary angioedema. J Allergy Clin Immunol. 1981;68:181-187.
23. Frank MM, Sergent JS, Kane MA, Alling DW. Epsilon aminocaproic acid therapy of hereditary angioneurotic edema: a double-blind study. N Engl J Med. 1972;286:808-812.
24. Sheffer AL, Austen KF, Rosen FS. Tranexamic acid therapy in hereditary angioneurotic edema. N Engl J Med. 1972;287:452- 454.
25. Visentin DE, Yang WH, Karsh J. C1 esterase inhibitor transfusion in patients with hereditary angioedema. Ann Allergy Asthma Immunol. 1988;80:457- 461.
26. Zingale LC, Zanichelli P, Deliliers DL, Cicardi M. Anaphylaxis in response to C1 esterase inhibitor in a patient with hereditary angioedema: successful treatment with DX088, a human plasma kallikrein inhibitor. Allergy Clin Immunol World Allergy Org. 2007;19: 159-163.
27. Bork K, Frank J, Grundt B, Schlattmann P, Nussberger J, Kreuz W. Treatment of acute edema attacks in hereditary angioedema with a bradykinin receptor-2 antagonist (Icatibant). J Allergy Clin Immunol. 2004;119:1497-1503.
28. Schapira M, Silver LD, Scott CF, et al. Prekallikrein activation and high-molecular-weight kininogen consumption in hereditary angioedema. N Engl J Med. 1983;308:1050 -1053.
29. Cugno M, Cicardi M, Coppola R, Agostoni A. Activation of factor XII and cleavage of high molecular weight kininogen during acute attacks in hereditary and acquired C1-inhibitor deficiencies. Immunopharmacology. 1996;33:361-364.
30. Schreiber AD, Kaplan AP, Austen KF. Inhibition by C1INH of Hagemann factor fragment activation of coagulation, fibrinolysis, and kinin generation. J Clin Invest. 1973;52:1402-1409.
31. Pixley RA, Schapira M, Colman RW. The regulation of human factor XIIa by plasma proteinase inhibitors. J Biol Chem. 1985;260: 1723-1729.
32. Weiss R, Silverberg M, Kaplan AP. The effect of C1 inhibition upon Hageman factor autoactivation. Blood. 1986;68:239 -243.
33. Harpel PC, Lewin MF, Kaplan AP. Distribution of plasma kallikrein between C-1 inactivator and alpha 2-macroglobulin in plasma utilizing a new assay for alpha 2-macroglobulin-kallikrein complexes. J Biol Chem. 1985;260:4257- 4263.
34. Brown EW, Ravindran S, Patston PA. The reaction between plasmin and C1-inhibitor results in plasmin inhibition by the serpin mechanism. Blood Coagul Fibrinolysis. 2002;13:711-714.
35. Mullertz S, Clemmensen I. The primary inhibitor of plasmin in human plasma. Biochem J. 1976;159:545-553.
36. Tosi M. Molecular genetics of C1 inhibitor. Immunology. 1998;119: 358-365.
37. Zuraw B, Herschbach J. Detection of C1 inhibitor mutations in patients with hereditary angioedema. J Allergy Clin Immunol. 2000;105:541-546.